HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models.

Abstract
We have presently studied the in vitro, ex vivo and in vivo immunopharmacological effects of VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid]. This compound reduced the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages stimulated "in vitro" with lipopolysaccharide (LPS), and it also modified the signaling pathways induced in these cells by LPS entailing reduced activation of NF-kappaB and p38 MAP kinase pathways along with up-regulation of ERK pathways. VGX-1027 appeared to spare T cell function as it was unable to modify the proliferation and/or secretion of IL-2, IFN-gamma and IL-4 induced in purified murine CD4+ T cells from stimulation with either CD3+CD28 or ConA. These effects on macrophages may account for the capacity of VGX-1027 to markedly ameliorate the course of both acute and chronic immunoinflammatory diseases in mice such as carrageenan-induced pleurisy, LPS-induced lethality and type II collagen-induced arthritis. Acute and subacute toxicological studies show that the drug is not toxic at the doses that exert biological effects in these preclinical models. These data warrant additional studies for the potential use of VGX-1027 in the clinical setting.
AuthorsIvana Stojanovic, Salvatore Cuzzocrea, Katia Mangano, Emanuela Mazzon, Djordje Miljkovic, Mingjun Wang, Marco Donia, Yousef Al Abed, Joseph Kim, Ferdinando Nicoletti, Stanislava Stosic-Grujicic, Mogens Claesson
JournalClinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 123 Issue 3 Pg. 311-23 (Jun 2007) ISSN: 1521-6616 [Print] United States
PMID17449326 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3-phenyl-4,5-dihydro-5-isoxazole acetic acid
  • Acetates
  • Cytokines
  • I-kappa B Proteins
  • Immunologic Factors
  • Lipopolysaccharides
  • Oxazoles
  • Acetylmuramyl-Alanyl-Isoglutamine
  • Mitogen-Activated Protein Kinases
Topics
  • Acetates (pharmacology, toxicity)
  • Acetylmuramyl-Alanyl-Isoglutamine (pharmacology)
  • Animals
  • Arthritis, Experimental (chemically induced, pathology, prevention & control)
  • CD4-Positive T-Lymphocytes (drug effects, metabolism)
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Cytokines (metabolism)
  • Female
  • I-kappa B Proteins (metabolism)
  • Immunologic Factors (pharmacology, toxicity)
  • Leukocytes, Mononuclear (drug effects, metabolism)
  • Lipopolysaccharides (pharmacology)
  • Macrophages, Peritoneal (drug effects, metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred CBA
  • Mice, Inbred DBA
  • Mitogen-Activated Protein Kinases (metabolism)
  • Oxazoles (pharmacology, toxicity)
  • Phosphorylation (drug effects)
  • Pleurisy (chemically induced, pathology, prevention & control)
  • Shock, Septic (chemically induced, mortality, prevention & control)
  • Spleen (cytology, drug effects)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: